Success Metrics

Clinical Success Rate
80.5%

Based on 33 completed trials

Completion Rate
80%(33/41)
Active Trials
6(12%)
Results Posted
48%(16 trials)
Terminated
8(16%)

Phase Distribution

Ph phase_3
14
27%
Ph phase_4
4
8%
Ph early_phase_1
2
4%
Ph phase_1
10
20%
Ph not_applicable
3
6%
Ph phase_2
18
35%

Phase Distribution

12

Early Stage

18

Mid Stage

18

Late Stage

Phase Distribution51 total trials
Early Phase 1First-in-human
2(3.9%)
Phase 1Safety & dosage
10(19.6%)
Phase 2Efficacy & side effects
18(35.3%)
Phase 3Large-scale testing
14(27.5%)
Phase 4Post-market surveillance
4(7.8%)
N/ANon-phased studies
3(5.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

76.7%

33 of 43 finished

Non-Completion Rate

23.3%

10 ended early

Currently Active

6

trials recruiting

Total Trials

51

all time

Status Distribution
Active(7)
Completed(33)
Terminated(10)
Other(1)

Detailed Status

Completed33
Terminated8
Recruiting5
Withdrawn2
Active, not recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
51
Active
6
Success Rate
80.5%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (3.9%)
Phase 110 (19.6%)
Phase 218 (35.3%)
Phase 314 (27.5%)
Phase 44 (7.8%)
N/A3 (5.9%)

Trials by Status

active_not_recruiting12%
recruiting510%
not_yet_recruiting12%
terminated816%
withdrawn24%
completed3365%
unknown12%

Recent Activity

Clinical Trials (51)

Showing 20 of 51 trialsScroll for more
NCT06976658Phase 2

Glucokinase Activator in Monogenic Diabetes

Recruiting
NCT05066672Phase 2

Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression

Completed
NCT04157335Phase 3

Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)

Terminated
NCT06310291Early Phase 1

VTP-1000 in Adults With Celiac Disease

Recruiting
NCT04965298Phase 3

Treating People With Idiopathic Pulmonary Fibrosis With the Addition of Lansoprazole

Recruiting
NCT03202303Phase 2

Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)

Recruiting
NCT03015610Phase 3

Genotype-tailored Treatment of Symptomatic Acid-Reflux in Children With Uncontrolled Asthma

Completed
NCT06565208Early Phase 1

First in Human SAD/MAD Safety and PK Study With Adult DMD Safety and PK Cohort

Completed
NCT03197662Phase 2

Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Prader-Willi Syndrome

Completed
NCT05919680Phase 2

A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).

Recruiting
NCT03721978Phase 3

REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

Completed
NCT06519422Phase 3

Tranexamic Acid for Anaemia Trial

Not Yet Recruiting
NCT04173533Phase 3

Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT

Active Not Recruiting
NCT05602688Not Applicable

Melissa Officinalis L. Supplementation for Emotional Health and Sleep Disturbance

Completed
NCT05097014Phase 4

CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD

Completed
NCT03227471Phase 1

A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis

Completed
NCT02629991Phase 2

Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome

Completed
NCT04371523Phase 3

Hydroxychloroquine to Prevent COVID-19 Disease Amongst Healthcare Workers

Withdrawn
NCT04486508Phase 3

Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19

Completed
NCT04467684Phase 1

Study Investigating the Safety, Tolerability, and PK, PD, of CB-0406

Completed

Drug Details

Intervention Type
DRUG
Total Trials
51